Fusion Pharmaceuticals

Full-Life Technologies

This company develops radiopharmaceuticals and radionuclide drug conjugates to treat cancer patients through targeted alpha therapy.

Alpha-9 Theranostics

This clinical-stage biotechnology company develops targeted radiopharmaceuticals to treat cancer patients by delivering radiation directly to tumours while sparing healthy tissue.

Aktis Oncology

This biotechnology company develops alpha-emitting radiopharmaceuticals to treat patients with solid tumor cancers.

Rayze Bio

RayzeBio develops targeted radiopharmaceutical therapies using alpha-emitting isotopes to treat patients with solid tumours and other cancers.

Nuclidium

This clinical-stage company develops copper-based radiopharmaceuticals for the diagnosis and treatment of cancer patients.

Ariceum Therapeutics

This clinical-stage biotechnology company develops targeted radiopharmaceutical therapies for the diagnosis and treatment of aggressive, hard-to-treat cancers.

Akiram Therapeutics

This biotech company develops targeted radiopharmaceuticals and radioimmunotherapies for patients with solid tumours and metastatic cancers.

Alpha-9

Alpha-9 Oncology develops targeted radiopharmaceuticals and imaging compounds for the treatment of patients with various types of cancer.